Big Pharma has put a Houston pharmacy squarely in the crosshairs of its quest to weed out copycat versions of wildly popular diabetes and weight loss drugs. Eli Lilly, the maker of the diabetes drug Mounjaro and weight loss drug Zepbound,

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why LLY stock is a buy.

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.